Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry

Jessica C. L. Notohardjo; Malou C. P. Kuppen; Hans M. Westgeest; Reindert J. A. van Moorselaar; Niven Mehra; Jules L. L. M. Coenen; Inge M. van Oort; Aad de Vos; Walter L. Vervenne; Alphons C. M. van den Bergh; Katja K. H. Aben; Diederik M. Somford; Andries M. Bergman; Carin A. Uyl-de Groot; Winald R. Gerritsen; Alfons J. M. van den Eertwegh

doi:10.1016/j.euf.2020.03.009

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry

Jessica C. L. Notohardjo^*, Malou C. P. Kuppen, Hans M. Westgeest, Reindert J. A. van Moorselaar, Niven Mehra, Jules L. L. M. Coenen, Inge M. van Oort, Aad de Vos, Walter L. Vervenne, Alphons C. M. van den Bergh, Katja K. H. Aben, Diederik M. Somford, Andries M. Bergman, Carin A. Uyl-de Groot, Winald R. Gerritsen, Alfons J. M. van den Eertwegh

^*Bijbehorende auteur voor dit werk

Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Onderzoeksoutput › Academic › peer review

2 Citaten (Scopus)

27 Downloads (Pure)

Samenvatting

Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 31, 2017. Outcome measurements and statistical analysis: Association of potential risk factors with OS was tested by Cox proportional hazard models after multiple imputation of missing baseline characteristics. A predictive score was computed from the regression coefficient and used to classify patients into risk groups. Results and limitations: Of 1011 mCRPC patients progressive on second-line LPD, 602 (60%) received third-line LPD. Patients receiving third-line LPD had a more favorable prognostic profile at baseline and longer median OS than patients with best supportive

Originele taal-2	English
Pagina's (van-tot)	788-796
Aantal pagina's	9
Tijdschrift	European Urology Focus
Volume	7
Nummer van het tijdschrift	4
DOI's	https://doi.org/10.1016/j.euf.2020.03.009
Status	Published - jul.-2021

Toegang tot document

10.1016/j.euf.2020.03.009

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer PopulationFinal publisher's version, 885 KBLicentie: Taverne

Handle.net

Permanente koppeling

Citeer dit

Notohardjo, J. C. L., Kuppen, M. C. P., Westgeest, H. M., van Moorselaar, R. J. A., Mehra, N., Coenen, J. L. L. M., van Oort, I. M., de Vos, A., Vervenne, W. L., van den Bergh, A. C. M., Aben, K. K. H., Somford, D. M., Bergman, A. M., Uyl-de Groot, C. A., Gerritsen, W. R., & van den Eertwegh, A. J. M. (2021). Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus, 7(4), 788-796. https://doi.org/10.1016/j.euf.2020.03.009

@article{271f8cdc567a4261a2e66bb7d36cae23,

title = "Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry",

abstract = "Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 31, 2017. Outcome measurements and statistical analysis: Association of potential risk factors with OS was tested by Cox proportional hazard models after multiple imputation of missing baseline characteristics. A predictive score was computed from the regression coefficient and used to classify patients into risk groups. Results and limitations: Of 1011 mCRPC patients progressive on second-line LPD, 602 (60%) received third-line LPD. Patients receiving third-line LPD had a more favorable prognostic profile at baseline and longer median OS than patients with best supportive",

keywords = "Life-prolonging drug, Real-world outcomes, Third line, Castration-resistant prostate cancer, ABIRATERONE ACETATE, ANTITUMOR-ACTIVITY, PROGNOSTIC MODEL, DOCETAXEL, ENZALUTAMIDE, SURVIVAL, CHEMOTHERAPY, MITOXANTRONE, CABAZITAXEL, PREDNISONE",

author = "Notohardjo, {Jessica C. L.} and Kuppen, {Malou C. P.} and Westgeest, {Hans M.} and {van Moorselaar}, {Reindert J. A.} and Niven Mehra and Coenen, {Jules L. L. M.} and {van Oort}, {Inge M.} and {de Vos}, Aad and Vervenne, {Walter L.} and {van den Bergh}, {Alphons C. M.} and Aben, {Katja K. H.} and Somford, {Diederik M.} and Bergman, {Andries M.} and {Uyl-de Groot}, {Carin A.} and Gerritsen, {Winald R.} and {van den Eertwegh}, {Alfons J. M.}",

year = "2021",

month = jul,

doi = "10.1016/j.euf.2020.03.009",

language = "English",

volume = "7",

pages = "788--796",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "De Tijdstroom/Elsevier",

number = "4",

}

Notohardjo, JCL, Kuppen, MCP, Westgeest, HM, van Moorselaar, RJA, Mehra, N, Coenen, JLLM, van Oort, IM, de Vos, A, Vervenne, WL, van den Bergh, ACM, Aben, KKH, Somford, DM, Bergman, AM, Uyl-de Groot, CA, Gerritsen, WR & van den Eertwegh, AJM 2021, 'Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry', European Urology Focus, vol. 7, nr. 4, blz. 788-796. https://doi.org/10.1016/j.euf.2020.03.009

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population : Results from the Dutch Castration-resistant Prostate Cancer Registry. / Notohardjo, Jessica C. L.; Kuppen, Malou C. P.; Westgeest, Hans M. et al.

In: European Urology Focus, Vol. 7, Nr. 4, 07.2021, blz. 788-796.

Onderzoeksoutput › Academic › peer review

TY - JOUR

T1 - Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population

T2 - Results from the Dutch Castration-resistant Prostate Cancer Registry

AU - Notohardjo, Jessica C. L.

AU - Kuppen, Malou C. P.

AU - Westgeest, Hans M.

AU - van Moorselaar, Reindert J. A.

AU - Mehra, Niven

AU - Coenen, Jules L. L. M.

AU - van Oort, Inge M.

AU - de Vos, Aad

AU - Vervenne, Walter L.

AU - van den Bergh, Alphons C. M.

AU - Aben, Katja K. H.

AU - Somford, Diederik M.

AU - Bergman, Andries M.

AU - Uyl-de Groot, Carin A.

AU - Gerritsen, Winald R.

AU - van den Eertwegh, Alfons J. M.

PY - 2021/7

Y1 - 2021/7

N2 - Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 31, 2017. Outcome measurements and statistical analysis: Association of potential risk factors with OS was tested by Cox proportional hazard models after multiple imputation of missing baseline characteristics. A predictive score was computed from the regression coefficient and used to classify patients into risk groups. Results and limitations: Of 1011 mCRPC patients progressive on second-line LPD, 602 (60%) received third-line LPD. Patients receiving third-line LPD had a more favorable prognostic profile at baseline and longer median OS than patients with best supportive

AB - Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 31, 2017. Outcome measurements and statistical analysis: Association of potential risk factors with OS was tested by Cox proportional hazard models after multiple imputation of missing baseline characteristics. A predictive score was computed from the regression coefficient and used to classify patients into risk groups. Results and limitations: Of 1011 mCRPC patients progressive on second-line LPD, 602 (60%) received third-line LPD. Patients receiving third-line LPD had a more favorable prognostic profile at baseline and longer median OS than patients with best supportive

KW - Life-prolonging drug

KW - Real-world outcomes

KW - Third line

KW - Castration-resistant prostate cancer

KW - ABIRATERONE ACETATE

KW - ANTITUMOR-ACTIVITY

KW - PROGNOSTIC MODEL

KW - DOCETAXEL

KW - ENZALUTAMIDE

KW - SURVIVAL

KW - CHEMOTHERAPY

KW - MITOXANTRONE

KW - CABAZITAXEL

KW - PREDNISONE

U2 - 10.1016/j.euf.2020.03.009

DO - 10.1016/j.euf.2020.03.009

M3 - Article

SN - 2405-4569

VL - 7

SP - 788

EP - 796

JO - European Urology Focus

JF - European Urology Focus

IS - 4

ER -